Literature DB >> 22330912

Broad-spectrum β-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48.

Olivier Mimoz1, Nicolas Grégoire, Laurent Poirel, Manuella Marliat, William Couet, Patrice Nordmann.   

Abstract

A lethal peritonitis model was induced in mice with a Klebsiella pneumoniae isolate producing the carbapenemase OXA-48. Administration of a single dose (up to 100 mg/kg) of the antibiotic piperacillin-tazobactam, imipenem-cilastatin, ertapenem, or cefotaxime had little or no impact on lethality. Ceftazidime had the highest efficacy in vivo, which mirrored its in vitro activity; this was not the case for carbapenems. Therefore, ceftazidime may be recommended for the treatment of infections due to OXA-48 producers if they do not coproduce an extended-spectrum β-lactamase or a plasmid-mediated AmpC cephalosporinase.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330912      PMCID: PMC3346608          DOI: 10.1128/AAC.06069-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals.

Authors:  Y Kita; T Yamazaki; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Genetic features of the widespread plasmid coding for the carbapenemase OXA-48.

Authors:  Laurent Poirel; Rémy A Bonnin; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

3.  Transfer of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae from Turkey to France.

Authors:  Marion Levast; Laurent Poirel; Amélie Carrër; Michel Deiber; Emmanuel Decroisette; Frank-Olivier Mallaval; Claire Lecomte; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2011-01-20       Impact factor: 5.790

4.  Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia.

Authors:  F Soriano; C Ponte; E Nieto; A Parra
Journal:  J Antimicrob Chemother       Date:  1996-08       Impact factor: 5.790

5.  Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France.

Authors:  Gaelle Cuzon; Jocelyne Ouanich; Remy Gondret; Thierry Naas; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

6.  Comparison of the effect of cefepime with four cephalosporins against pneumococci with various susceptibilities to penicillin, in vitro and in the mouse peritonitis model.

Authors:  J D Knudsen; K Fuursted; N Frimodt-Møller; F Espersen
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

7.  Broad-spectrum beta-lactams for treating experimental peritonitis in mice due to Escherichia coli producing plasmid-encoded cephalosporinases.

Authors:  Sophie Vimont; Daniel Aubert; Jean-Xavier Mazoit; Laurent Poirel; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2007-09-04       Impact factor: 5.790

Review 8.  Has the era of untreatable infections arrived?

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2009-09       Impact factor: 5.790

Review 9.  Diversity, epidemiology, and genetics of class D beta-lactamases.

Authors:  Laurent Poirel; Thierry Naas; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

Review 10.  Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections.

Authors:  Karen Bush
Journal:  Crit Care       Date:  2010-06-29       Impact factor: 9.097

View more
  13 in total

1.  First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world.

Authors:  Amy J Mathers; Kevin C Hazen; Joanne Carroll; Anthony J Yeh; Heather L Cox; Robert A Bonomo; Costi D Sifri
Journal:  J Clin Microbiol       Date:  2012-11-21       Impact factor: 5.948

Review 2.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 3.  Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance.

Authors:  Johann D D Pitout; Patrice Nordmann; Laurent Poirel
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

Review 4.  OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.

Authors:  Sara E Boyd; Alison Holmes; Richard Peck; David M Livermore; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2022-07-20       Impact factor: 5.938

5.  Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013.

Authors:  S Pollett; S Miller; J Hindler; D Uslan; M Carvalho; R M Humphries
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

6.  Diversity of Carbapenemase-Producing Escherichia coli Isolates in France in 2012-2013.

Authors:  Lauraine Gauthier; Laurent Dortet; Garance Cotellon; Elodie Creton; Gaëlle Cuzon; Valérie Ponties; Rémy A Bonnin; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.

Authors:  Dora E Wiskirchen; Patrice Nordmann; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

Review 8.  Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat.

Authors:  Yamuna Devi Bakthavatchalam; Shalini Anandan; Balaji Veeraraghavan
Journal:  J Glob Infect Dis       Date:  2016 Jan-Mar

9.  Structural Analysis of The OXA-48 Carbapenemase Bound to A "Poor" Carbapenem Substrate, Doripenem.

Authors:  Krisztina M Papp-Wallace; Vijay Kumar; Elise T Zeiser; Scott A Becka; Focco van den Akker
Journal:  Antibiotics (Basel)       Date:  2019-09-11

10.  In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.

Authors:  Fatma Erdem; Ayham Abulaila; Zerrin Aktas; Oral Oncul
Journal:  Antimicrob Resist Infect Control       Date:  2020-05-19       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.